On December 30, 2023, Amy Bachrodt, Senior Vice President of Maze Therapeutics (NASDAQ: MAZE), sold 5,000 shares of the company’s stock at an average price of $40.08. This transaction totaled $200,400 and resulted in Bachrodt’s remaining shareholding of 12,965 shares, now valued at approximately $519,637.20. The sale reflects a significant reduction in her position, representing a 27.83% decrease.
The transaction was disclosed in a filing with the Securities and Exchange Commission, which is publicly accessible for further details. The sell-off comes amid a period of fluctuating stock performance for Maze Therapeutics, a clinical-stage biotechnology firm based in the United States.
Current Stock Performance and Analyst Evaluations
Maze Therapeutics opened trading on Thursday at $41.43. The company’s market capitalization stands at $1.99 billion, with a price-to-earnings (PE) ratio of -1.98. Over the past year, Maze’s stock has seen a low of $6.71 and a high of $43.29. The stock’s 50-day and 200-day moving average prices are $36.58 and $24.58, respectively.
Recent evaluations from various analysts indicate a generally positive outlook for Maze Therapeutics. On November 7, Wedbush raised its target price for the company from $35.00 to $36.00 while maintaining an “outperform” rating. Similarly, JPMorgan Chase & Co. increased its target from $27.00 to $37.00, assigning an “overweight” rating. Lifesci Capital recently upgraded Maze to a “strong-buy” rating, while Raymond James Financial issued an “outperform” rating with a price target of $48.00 on November 13.
Overall, MarketBeat reports that three analysts have rated the stock as a Strong Buy, eight have assigned a Buy rating, and one has given it a Sell rating. The consensus price target currently stands at $43.38.
Investment Trends and Institutional Activity
Institutional investors have been adjusting their stakes in Maze Therapeutics recently. CWM LLC initiated a new stake in the company during the second quarter, valued at approximately $28,000. Ameritas Investment Partners Inc. increased its holdings by 82.6% in the third quarter, now owning 1,632 shares valued at $42,000 after acquiring an additional 738 shares.
In a significant move, Russell Investments Group Ltd. raised its stake in Maze Therapeutics by 947.8% in the third quarter, now controlling 1,907 shares worth $49,000 after adding 1,725 shares to its portfolio. Additionally, China Universal Asset Management Co. Ltd. acquired a new position in the company valued at approximately $52,000 during the same quarter.
Maze Therapeutics operates at the forefront of biotechnology, focusing on the discovery and development of novel therapeutics through insights derived from human genetics and genomics. By employing advanced data analytics and proprietary platforms, the company seeks to identify targets with strong genetic validation, aiming to de-risk early drug discovery and accelerate the development of innovative treatments for serious diseases. Since its founding, Maze has built a diversified pipeline that encompasses various therapeutic areas, including metabolic and immunological diseases.
For ongoing insights and updates on Maze Therapeutics, interested parties can subscribe to daily summaries from MarketBeat, which provide the latest news and analyst ratings related to the company.
